SEC Comment Letter for Akero Therapeutics, Inc. (AKRO) (CIK 0001744659) — May 20, 2020
Akero Therapeutics, Inc. (AKRO) (CIK 0001744659)
Date: May 20, 2020 · CIK: 0001744659 · Accession: 0000000000-20-004520
AI Filing Summary & Sentiment
Letter
United States securities and exchange commission logo May 20, 2020 Bill White CFO and Head of Corporate Development Akero Therapeutics, Inc. 170 Harbor Way, 3rd Floor South San Francisco, California 94080 Re:Akero Therapeutics, Inc. Draft Registration Statement on Form S-1 Submitted May 15, 2020 CIK No. 0001744659 Dear Mr. White: This is to advise you that we do not intend to review your registration statement. We request that you publicly file your registration statement no later than 48 hours prior to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Courtney Lindsay at (202) 551-7237 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
United States securities and exchange commission logo
May 20, 2020
Bill White
CFO and Head of Corporate Development
Akero Therapeutics, Inc.
170 Harbor Way, 3rd Floor
South San Francisco, California 94080
Re:Akero Therapeutics, Inc.
Draft Registration Statement on Form S-1
Submitted May 15, 2020
CIK No. 0001744659
Dear Mr. White:
This is to advise you that we do not intend to review your registration statement.
We request that you publicly file your registration statement no later than 48 hours prior
to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you that the company and its management are responsible for the
accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or
absence of action by the staff.
Please contact Courtney Lindsay at (202) 551-7237 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences